[1]王小凤,刘晶,罗桑曲珍,等.他汀类药物用于甲状腺相关性眼病的研究进展[J].国际内分泌代谢杂志,2023,43(04):330-332.[doi:10.3760/cma.j.cn121383-20220406-04015]
　Wang Xiaofeng,Liu Jing,Luo Sangquzhen,et al.Research progress of statins for thyroid related eye diseases[J].International Journal of Endocrinology and Metabolism,2023,43(04):330-332.[doi:10.3760/cma.j.cn121383-20220406-04015]
点击复制

他汀类药物用于甲状腺相关性眼病的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年04期
页码:
330-332
栏目:
综述
出版日期:
2023-07-20

文章信息/Info

Title:
Research progress of statins for thyroid related eye diseases
作者:
王小凤1; 刘晶2; 罗桑曲珍3; 宋智慧4
1内蒙古锡林郭勒盟蒙医医院临床药学科,锡林浩特市 026000; 2新疆医科大学附属中医医院药学部,乌鲁木齐市 830000; 3西藏拉萨市人民医院药学部,拉萨市 850000; 4首都医科大学附属北京同仁医院药学部,北京 100730
Author(s):
Wang Xiaofeng1;  Liu Jing2;  Luo Sangquzhen3;  Song Zhihui4
1Department of Clinical Pharmacy, Xilingol Mongolian Hospital, Xilinhot 026000, China; 2Department of Pharmacy, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, China; 3Department of Pharmacy, Lhasa People's Hospital, Lhasa 850000, China; 4Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
关键词:
甲状腺相关眼病;  他汀类药物;  胆固醇;  调脂药
Keywords:
Thyroid associated ophthalmopathy;  Statins;  Cholesterol;  Lipid-lowering drug
DOI:
10.3760/cma.j.cn121383-20220406-04015
摘要:
甲状腺相关性眼病(thyroid associated ophthalmopathy,TAO)是一种发病率相对较低,但会严重威胁视力的疾病,目前治疗药物有限。他汀类药物由于独特的抗炎、免疫调节作用,对TAO患者有潜在的获益,不仅可降低甲状腺功能亢进患者发生Graves眼病的风险,还可改善预后,但其他降脂药对TAO患者的获益目前多停留在体外研究阶段,仅提示可能有潜在获益,尤其是Kexin样前转化酶枯草杆菌蛋白酶家族的第9个成员(PCSK9抑制剂)以及贝特类药物,未来需要更多的临床研究深入探索。
Abstract:
Thyroid associated ophthalmopathy(TAO)is a disease with a relatively low incidence, but it can seriously threaten vision, and current therapeutic agents are limited. Statins have been found to have potential benefits for TAO patients due to their unique anti-inflammatory and immunomodulatory effects, not only reducing the risk of Graves' ophthalmopathy in patients with hyperthyroidism, but also improving the prognosis. The benefits of other lipid-lowering drugs for TAO patients currently remain in vitro, only suggesting that there may be potential benefits, especially proprotein-convertase-subtilisin-kexin type-9(PCSK9)inhibitors as well as fibrates, which need to be explored in depth in more clinical studies in the future.

参考文献/References:

[1] Kahaly GJ.Management of Graves thyroidal and extrathyroidal disease:an update[J].J Clin Endocrinol Metab,2020,105(12):3704-3720.DOI:10.1210/clinem/dgaa646.
[2] Pritchard J,Horst N,Cruikshank W,et al.Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts[J].J Immunol,2002,168(2):942-950.DOI:10.4049/jimmunol.168.2.942.
[3] 叶小珍,王坚.成纤维细胞在Graves眼病发病机制中的作用及相关免疫治疗[J].中国全科医学,2009,12(11):1016-1018.DOI:10.3969/j.issn.1007-9572.2009.11.036.
[4] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.甲状腺功能亢进症基层诊疗指南(2019年)[J].中华全科医师杂志,2019,18(12):1118-1128.DOI:10.3760/cma.j.issn.1671-7368.2019.12.002.
[5] Bartalena L,Kahaly GJ,Baldeschi L,et al.The 2021 European Group on Graves' orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43G67.DOI:10.1530/EJE-21-0479.
[6] Stein JD,Childers D,Gupta S,et al.Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease[J].JAMA Ophthalmol,2015,133(3):290-296.DOI:10.1001/jamaophthalmol.2014.5103.
[7] Marinò M,Lanzolla G,Marcocci C.Statins:a new hope on the horizon of Graves orbitopathy?[J].J Clin Endocrinol Metab,2021,106(7):e2819-e2821.DOI:10.1210/clinem/dgab184.
[8] Nilsson A,Tsoumani K,Planck T.Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves' disease[J].J Clin Endocrinol Metab,2021,106(5):1325-1332.DOI:10.1210/clinem/dgab070.
[9] Li X,Li S,Fan W,et al.Recent advances in Graves ophthalmopathy medical therapy:a comprehensive literature review[J].Int Ophthalmol,2023,43(4):1437-1449.DOI:10.1007/s10792-022-02537-6.
[10] Sabini E,Mazzi B,Profilo MA,et al.High serum cholesterol is a novel risk factor for Graves' orbitopathy:results of a cross-sectional study[J].Thyroid,2018,28(3):386-394.DOI:10.1089/thy.2017.0430.
[11] 叶小珍,黄珊珊,刘隽,等.高胆固醇血症:甲状腺相关性眼病新的发病危险因素?[J].中华内科杂志,2019,58(11):823-825.DOI:10.3760/cma.j.issn.0578-1426.2019.11.007.
[12] Lanzolla G,Sabini E,Profilo MA,et al.Relationship between serum cholesterol and Graves' orbitopathy(GO):a confirmatory study[J].J Endocrinol Invest,2018,41(12):1417-1423.DOI:10.1007/s40618-018-0915-z.
[13] Naselli A,Moretti D,Regalbuto C,et al.Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of Graves' ophthalmopathy to parenteral corticosteroids[J].Front Endocrinol(Lausanne),2020,11:609895-609905.DOI:10.3389/fendo.2020.609895.
[14] Lanzolla G,Sabini E,Leo M,et al.Statins for Graves' orbitopathy(STAGO):a phase 2,open-label,adaptive,single centre,randomised clinical trial[J].Lancet Diabetes Endocrinol,2021,9(11):733-742.DOI:10.1016/S2213-8587(21)00238-2.
[15] Reynolds AL,Del Monte MA,Archer SM.The effect of oral statin therapy on strabismus in patients with thyroid eye disease[J].J AAPOS,2018,22(5):340-343.DOI:10.1016/j.jaapos.2018.04.009.
[16] Bifulco M,Ciaglia E.Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities[J].Endocrine,2016,53(3):649-650.DOI:10.1007/s12020-015-0762-z.
[17] Croons V,De Meyer I,Houten SM,et al.Effect of statins on the viability of macrophages and smooth muscle cells[J].J Cardiovasc Pharmacol,2010,55(3):269-275.DOI:10.1097/FJC.0b013e3181d0bec3.
[18] Shahida B,Johnson PS,Jain R,et al.Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves' ophthalmopathy patients[J].Endocr Connect,2019,8(9):1230-1239.DOI:10.1530/EC-19-0319.
[19] Pasquali D,Pierantoni GM,Fusco A,et al.Fenofibrate increases the expression of high mobility group AT-hook 32(HMGA2)gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy[J]. J Mol Endocrinol,2004,33(1):133-143.DOI:10.1677/jme.0.0330133.
[20] Lee GE,Kim J,Lee JS,et al.Role of proprotein convertase subtilisin/kexin type 9 in the pathogenesis of Graves' orbitopathy in orbital fibroblasts[J].Front Endocrinol(Lausanne),2021,11:607144.DOI:10.3389/fendo.2020.607144.

相似文献/References:

[1]冯会 孙建平 段薇.甲状腺相关眼病治疗新进展[J].国际内分泌代谢杂志,2020,40(02):104.[doi:10.3760/cma.j.issn.1673-4157.2020.02.008]
　Feng Hui,Sun Jianping,Duan Wei.New progress in the treatment of thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2020,40(04):104.[doi:10.3760/cma.j.issn.1673-4157.2020.02.008]

备注/Memo

备注/Memo:
通信作者:宋智慧,Email:zhhsong2009@126.com
更新日期/Last Update: 2023-08-15